Xilingio M 10mg/5mg/1000mg Tablet ER is a combination oral antidiabetic medication containing Empagliflozin 10mg, Linagliptin 5mg, and Metformin 1000mg in an extended-release formulation. It is indicated for the management of type 2 diabetes mellitus in adults, particularly for patients inadequately controlled on monotherapy or dual therapy. Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, reduces renal glucose reabsorption, promoting glycosuria and lowering blood glucose levels. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin hormone activity, increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity. The extended-release formulation allows for once-daily dosing, improving patient adherence and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Xilingio M should be used alongside diet and exercise to achieve optimal glycemic control. Caution is advised in patients with renal impairment, hepatic dysfunction, or risk factors for lactic acidosis. Regular monitoring of renal function, blood glucose, and potential adverse effects such as urinary tract infections or hypoglycemia is recommended. This combination therapy offers a comprehensive approach to glycemic management by targeting multiple pathophysiological mechanisms of type 2 diabetes.